From the blurb included in the release of blinded data last March:--
quote:--
The company plans an analysis of the unblinded data from these 20 study participants to be performed during Q3 2016.
This will include assessment of the immunological endpoints including T cell response, as well as clinical and virological data. unquote
The last couple of years has seen very little in the way of communication from our employees in our VAX Division as to how things are going ... what are their opinions on various aspects of how this whole effort that we are paying for is progressing. The quote above shows that even by their own sanctioned statements we should be able to expect more ...
And just out of curiosity ... not a big deal I admit ... why do the test subjects either have 1 shot in one arm or one shot in each of two arms? ... if the HSV-2 virus hides in the nerves at the base of the spine then why not inject the vaccine down somewhere close to the base of the spine?
Cheers
Questions for AGM?, page-22
-
- There are more pages in this discussion • 112 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
-0.300(1.64%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.29 | $18.30 | $17.65 | $181.7K | 10.18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30 | $17.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.00 | 499 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |